Accelerating the digital revolution in life sciences.

Featured company

Chai Discovery

Engineering better molecules using artificial intelligence

learn more

Featured company

Modal Labs

High-performance AI infrastructure

learn more

Featured company

Enveda Biosciences

Unlocking the planet's chemistry to discover next-generation therapies

learn more

Featured company

Recursion

Recursion's mission is to decode biology to radically improve lives by advancing a biological discovery platform at the speed of technology platforms.

learn more

Portfolio companies

We partner with entrepreneurs, academics, and engineers to turn their groundbreaking ideas into dominant businesses that span the tech and bio ecosystem.
Text Link

Achira

Foundation simulation models for drug discovery

Text Link

Aspect Biosystems

Building a new class of regenerative medicines

Text Link

Automata

Next-generation lab automation and data management

Text Link

Axiom

Building AI models to predict the toxicity of drug candidates

Text Link

BioRender

Defining the future of scientific communication

Text Link

Chai Discovery

Engineering better molecules using artificial intelligence

Text Link

Convoke

Automating drug development knowledge work

Text Link

Enveda Biosciences

Unlocking the planet's chemistry to discover next-generation therapies

Text Link

Fiveonefour

Build and deploy data-intensive apps with ease

Text Link

Kaleidoscope Bio

Software to supercharge how scientific teams collaborate, manage experiments, and track decision-making

Text Link

Kimia Therapeutics

Developing a drug discovery engine using Chemotype Evolution to generate extensive datasets

Text Link

Lamin

Open-source software infrastructure for the modern lab

Text Link

Modal Labs

High-performance AI infrastructure

Text Link

Monte Rosa Therapeutics

Geometric deep learning for rational design of next generation protein degrader therapeutics

Text Link

NewLimit

Treating age-related disease to extend human healthspan

Text Link

Odyssey Therapeutics

Next generation precision medicines for cancer and inflammatory diseases

Text Link

Stately Bio

ML-powered cellular imaging platform for regenerative medicine

Text Link

Tamarind Bio

Easy to use computational biology tools for drug discovery

Search open roles at our portfolio companies

view job board
Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for Biology
GEN Edge

The Startup Building An Operating System For Biotech AI
Forbes

NewLimit is using epigenetic reprogramming to tackle age related disease
BiotechTV

AI is disrupting drug discovery faster than expected
Yahoo Finance

With new AI deal, Eli Lilly and Chai Discovery kick off a 'year of deployment' in pharma
Endpoints News

BioRender Gives AI A Visual Language For Science
Forbes

How a Medical Illustrator Built 'Canva for Science'
Inc.

Chai Discovery becomes newest AI unicorn, raising $130M Series B at $1.3B valuation
Endpoints News

Anti-aging biotech NewLimit brings in Eli Lilly as investor, raising $45M
Endpoints News

AI Infrastructure Startup Modal Labs Raises $80 Million
Bloomberg

Modal Labs hits unicorn status with $87M raise
Axios

OpenAI-backed Chai Discovery’s brainiac quartet aims to design drugs on the computer
Endpoints News

Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B
Fierce Biotech

Novartis extends deal spree with $120M for Monte Rosa's immune degraders
Endpoints News

Odyssey gets $213M Series D after backing out of IPO
Endpoints News

Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio
Fierce Biotech

Enveda collects another $150M for I&I drug, sprawling pipeline of preclinical assets
Endpoints News

Biotech’s Latest Unicorn Uses AI to Mine Nature’s Medicine Chest
Bloomberg

Why evolution designed us to die fast, & how we can change that
Dwarkesh Podcast

Convoke raises seed for AI biopharma tool
Axios

OpenAI-backed Chai raises $70mn for AI-driven drug discovery
Financial Times

Making Old Cells Young Again. For Real
Core Memory

AI-powered drug discovery with Chai Discovery
No Priors

OpenAI-backed startup releases new AI models
Endpoints News

NewLimit's Anti-Aging Bounty
Timmerman Report

The Company Trying to Reprogram Aging
Core Memory

Brian Armstrong’s NewLimit raises a $130M Series B, laying out road map for anti-aging drugs
Endpoints News

NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to develop age-reversing treatments
TechCrunch

Sanofi backs Enveda's AI-plus-nature approach to drug discovery
FirstWord Pharma

Ex-Calico scientist launches Stately Bio with new way to study cells
Endpoints News

Can AI replace animal testing? A new biotech launches to find out
Endpoints News

New kids on the block: A new generation of VCs ventures into biotech
STAT News

Nvidia, Dimension back startup building synthetic datasets for AI drug discovery
FirstWord Pharma

Nvidia-backed Achira debuts, blending AI and physics to model molecules
Endpoints News

Deepseek Shocked Silicon Valley but Its Not Earth Shaking for Biotech
Timmerman Report

Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies
Endpoints News

Investing In Aspect Biosystems
Blog

Techbio VC Dimension upsizes for $500M second fund
BioCentury

Dimension's Zavain Dar talks about raising a $500M second fund
Biotech TV

The 2nd Dimension: VC raises $500M fund for entrepreneurs pioneering life sci, tech
Fierce Bio

Dimension Books $500 Million for Second Life Sciences Venture Fund
WSJ

Dimension raises $500M second fund for investing at the intersection tech and life sciences
TechCrunch

Young biotech venture firm raises $500 million for its second fund
STAT News

Dimension nabs $500M second fund for 'still contrary' intersection of bio and machine learning
Endpoints News

VC Firm Dimension Raises $500 Million to Bet on AI and Medicine
Bloomberg

Dimension gets $500M to bankroll biotech’s convergence with tech
BioPharma Drive

VC firm raises $500 million for fund aimed at intersection of tech and life sciences
Axios

Dimension Raises $500M to Seize the Tech Driven Biology Future
Timmerman Report

This is just the beginning. Make no small plans.
Dimension

Announcing Dimension II
Dimension

Computational Techniques Are Driving a Tidal Shift in Therapeutic Protein Design
Timmerman Report

Investing in Monte Rosa Therapeutics
Blog

Investing in Chai Discovery
Blog

The State of AI in Drug Discovery
GEN Biotechnology

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas
Endpoints News

AI Drug Discovery Startup Enveda Raises $130 Million
Bloomberg

AI protein-prediction tool AlphaFold3 is now more open
Nature

Enveda raises $55M to combine ancient remedies with AI for drug discovery
Tech Crunch

Enveda Begins Clinical Trial For Drug Derived From Nature Using AI
Forbes

In biotech, time is money
GEN Biotechnology

Introducing Chai-1: Decoding the molecular interactions of life
Chai Discovery Team

OpenAI, Thrive Capital Back Six-Month-Old AI Drug Discovery Startup
BNN Bloomberg

With a fresh $100M, Monte Rosa CEO details plans to move several molecular glues into the clinic
Endpoints News

The Difference Is the Data: Drug Discovery's AI Revolution
GEN Biotechnology

A Conversation with Kimia’s CEO, Stig Hansen
Stifel

Biocom 2024: Developing new AI capabilities (and maybe going faster, too)
Bio World

The Endpoints Slack interview: Zavain Dar on starting a new VC, trusting the process with the 76ers, and Apple's VR future
Endpoints News

Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett
Touching Base

Kimia Therapeutics secures $55M to supercharge co-founder’s platform, create ‘next-generation Carmot’
Endpoints

The Generalist: Zavain Dar, GP at Dimension on investing at the bleeding edge of technology and life sciences
The Generalist

Investing at the bleeding edge of technology and life sciences.

Dimension leads $40M round for lab automation company Automata Technologies
Endpoints

Coinbase founder Brian Armstrong raises $40 million for NewLimit, a startup that wants to ‘cure aging’
Fortune

NewLimit, cofounded by Coinbase CEO Brian Armstrong, raises $40M to extend life
TechCrunch

Eric Newcomer: A New Dimension
Dead Cat Podcast

I wanted to hear why Goulburn and Dar, general partners at Lux Capital, and Li, a general partner at Obvious Ventures, decided to embark on the long, hard trek of building their own firm.

New York Bio Breakfast Series
New York Bio

NewYork BIO's breakfast series has gone virtual! Providing engaging speakers on innovation, clinical development, patient engagement and more cutting topics across the biopharmaceutical industry.

Homeroom Podcast : Adam Goulburn
Homeroom Podcast

Adam Goulburn is the co-founder and Managing Partner of Dimension, a $300 million fund focused on investing in companies at the intersection of medicine and data science.

New VC Firm Dimension Gets $350 Million as Healthcare Venture Fundraising Remains High
Wall Street Journal

New VC Firm Dimension Gets $350 Million as Healthcare Venture Fundraising Remains High

Three venture investors weigh in on the future of biotech as they launch a new $350M fund
Fortune

Three venture investors weigh in on the future of biotech as they launch a new $350M fund

As Tech Giants Fall, Tech-Focused VC Fund Rakes in $350M
BioSpace

As Tech Giants Fall, Tech-Focused VC Fund Rakes in $350M

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M
Fierce Biotech

Creating a new dimension: Biotech VC merging tech and life sciences unveils with $350M

Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’
BioPharma Dive

Three VCs launch Dimension, a new firm with plans to fuel biotech’s ‘digitization’

Focused exclusively on life sciences, three top investors set out on their own
STAT

Focused exclusively on life sciences, three top investors set out on their own

‘Siloing is just so outdated’: New $350M VC fund aims to digitize life sciences
Endpoints

‘Siloing is just so outdated’: New $350M VC fund aims to digitize life sciences

Dimension Debuts With 350M To Back Startups That Digitize Biology
Timmerman Report

Dimension Debuts With 350M To Back Startups That Digitize Biology

These Venture Veterans Have Launched A $350 Million Fund Aimed At Digitizing Life Sciences
Forbes

These Venture Veterans Have Launched A $350 Million Fund Aimed At Digitizing Life Sciences

Sherry Liu
Sherry Liu
Deniz Kavi
Deniz Kavi
Zhenping Zhu
Zhenping Zhu
Jian Peng
Jian Peng
Katya Shteyn
Katya Shteyn
Ryan Marien
Ryan Marien
Shiz Aoki
Shiz Aoki
Nikhil Namburi
Nikhil Namburi
Erik Bernhardsson
Erik Bernhardsson
Gary Glick
Gary Glick
Nic Joseph
Nic Joseph
Vikas Velagapudi
Vikas Velagapudi
Rami Hathwar
Rami Hathwar
Frank Li
Frank Li
Anna Bitton
Anna Bitton
Alex Beatson
Alex Beatson
Shayna Fischer
Shayna Fischer
Bauer LeSavage, PhD
Bauer LeSavage, PhD
Tamer Mohamed
Tamer Mohamed
Brandon White
Brandon White
Theofanis Karaletsos
Theofanis Karaletsos
John Chodera
John Chodera
Maged Korga Ahmed
Maged Korga Ahmed
Alex Telford
Alex Telford
Akshay Tambe
Akshay Tambe
Nick Boyd
Nick Boyd
April Schleck
April Schleck
Chloe Hsu
Chloe Hsu
Josh Meier
Josh Meier
Jack Dent
Jack Dent
Rich Stoner
Rich Stoner
Tim Delisle
Tim Delisle
Chris Crane
Chris Crane
Reha Mathur
Reha Mathur
Markus Warmuth
Markus Warmuth
Ray Fucini
Ray Fucini
Jack Sadowsky
Jack Sadowsky
Amy Zhen
Amy Zhen
Stig Hansen
Stig Hansen
Mostafa ElSayed
Mostafa ElSayed
Simon Barnett
Simon Barnett
Jacob Kimmel
Jacob Kimmel
Greg Johnson
Greg Johnson
Brian Armstrong
Brian Armstrong
Blake Byers
Blake Byers
David Yen
David Yen
Sunny Sun
Sunny Sun
Alex Wolf
Alex Wolf
Ahmed Elnaiem
Ahmed Elnaiem
Bogdan Knezevic
Bogdan Knezevic
Viswa Colluru
Viswa Colluru
Nan Li
Nan Li
Adam Goulburn, PhD
Adam Goulburn, PhD
Zavain Dar
Zavain Dar
Eric Crumb (Sample Portfolio CEO)
Eric Crumb (Sample Portfolio CEO)